Yourgene Health PLC Twin Pregnancy study published using IONA(R) Test
March 19 2021 - 2:00AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
19 March 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Twin Pregnancy study published using Yourgene's IONA(R) Test
Manchester, UK - 19 March 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, welcomes the paper
published in the American Journal of Obstetrics and Gynecology by
Khalil et al., titled: "Non-invasive Prenatal Screening in Twin
Pregnancies with cell-free DNA using the IONA(R) Test: a
prospective multicentre study."
The article details a multicentre study that took place in six
fetal medicine centres across the UK, using Yourgene's IONA(R) test
to establish the screening performance of cell-free DNA (cfDNA) for
the three common trisomies in twin pregnancies. The study confirmed
that cfDNA testing is the most accurate screening test for
trisomy(1) 21 in twin pregnancies, with screening performance
similar to single pregnancies, and failure rates of just 0.31%. It
was concluded that the predictive accuracy for trisomies 18 and 13
may be lower than for trisomy 21 but, given the low false positive
rate, it was determined that offering first line screening of cfDNA
to women with twin pregnancies is appropriate and should be
considered as the primary screening test for trisomies in twin
pregnancies as well as in single pregnancies.
The study is a positive development as previously several
organisations have recommended against cfDNA in twin pregnancies,
calling for larger prospective studies, despite the potential
advantages of non-invasive prenatal testing (NIPT) in twin
pregnancies being even greater than in single pregnancies. The
multicentre study was carried out with six leading NHS fetal
medicine centres in England. The lead author, Dr Asma Khalil, is a
global expert in twin pregnancies, based at St George's University
Foundation Hospital NHS Trust in South London. Yourgene has an
existing relationship with St George's NHS Trust Foundation for its
IONA (R) Nx NIPT Workflow, which underpins their own brand NIPT,
the "St George's Antenatal Fetal Evaluation (SAFE) Test" which is
run in their own lab.
Read the full paper here:
https://www.sciencedirect.com/science/article/pii/S0002937821000284
Lyn Rees, CEO of Yourgene, commented: "It is great to have the
clinical validation of NIPT screening in twin pregnancies fully
recognised. NIPT lowers the need for invasive testing and the
consequent fetal loss rate, providing a safer option for expectant
mothers, especially in twin pregnancies. The study concluded that
NIPT should be considered as the primary test and part of the
clinical pathway for all pregnancies, an important milestone for
non-invasive testing which confirms the key advantages of our
IONA(R) Test."
(1) - Trisomy - a condition in which an extra copy of a
chromosome is present in the cell nuclei, causing development
abnormalities
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584
391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZZGMFGRKGMZZ
(END) Dow Jones Newswires
March 19, 2021 03:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024